FutureMIND · Training Europe’s Future Leaders in AI-driven Neuro-Oncology Diagnostics and Discovery

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Project objective

Neuro-oncology, at the crossroads of neuroscience and cancer care, plays a crucial role in treating some of the most aggressive and complex malignancies, such as glioblastomas. Despite recent advancements in research and technoloNeuro-oncology, at the crossroads of neuroscience and cancer care, plays a crucial role in treating some of the most aggressive and complex malignancies, such as glioblastomas. Despite recent advancements in research and technology, the field continues to face major hurdles in early detection, risk-adapted surgery, accurate tumour classification, and the development of effective personalized treatments, underscoring the urgent need for innovative solutions to improve patient outcomes. Current advancements in computer science, particularly in artificial intelligence (AI), are revolutionizing medicine and offer unprecedented opportunities to improve areas that have historically seen limited progress, such as neuro-oncological care. However, critical gaps remain between technical innovations and their clinical application. Moreover, physicians often lack the technical background to fully utilize AI, while computer science developments may not always address clinical realities. The FutureMIND Doctoral Network aims to bridge these divides and fill in the gap of holistic experts needed to advance AI-driven diagnostics and discovery in neuro-oncology. FutureMIND brings together leading researchers, clinicians and entrepreneurs from eight countries to train 14 Doctoral Candidates (DCs) across different disciplines and sectors. By the end of FutureMIND, the DCs will be equipped to advance digital medicine as a new clinical tool to tackle brain cancers, with foreseeable impact on thousands of patients. Importantly, FutureMIND will prepare a new generation of European experts capable of addressing future challenges and of preparing the EU to sovereignly lead the digital transformation in neuro-oncology, paradigmatically for other areas of medical care.

Original text from CORDIS.

Participants

• RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG · HeidelbergCoordinatorGermany
• BRAINLAB SE · MUNCHENGermany
• CERCARE MEDICAL APS · Aarhus CDenmark
• DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG · HeidelbergGermany
• ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM · RotterdamNetherlands
• FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG · ErlangenGermany
• FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III · MadridSpain
• Heidelberg Epignostix GmbH · HeidelbergCity levelGermany
• INVENIO IMAGING INC · Santa ClaraCity levelUnited States
• Johner Institut GmbH · KonstanzGermany
• KAROLINSKA INSTITUTET · STOCKHOLMSweden
• OXFORD NANOPORE TECHNOLOGIES LTD · OxfordUnited Kingdom
• PROTEOTYPE DIAGNOSTICS LTD · CambridgeUnited Kingdom
• THE QUEEN'S UNIVERSITY OF BELFAST · BELFASTUnited Kingdom
• THE UNIVERSITY OF NOTTINGHAM · NottinghamUnited Kingdom
• UNIVERSIDAD AUTONOMA DE MADRID · MadridSpain
• UNIVERSITETET I OSLO · OsloNorway

Links

• View on CORDIS
• DOI: 10.3030/101312148